PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
Study identifier:2592-101 (PROCLAIM)
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
PROCLAIM: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure
Medical condition
Congestive Heart Failure
Phase
Phase 2
Healthy volunteers
No
Study drug
AC2592, placebo
Sex
All
Actual Enrollment
61
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2005
Primary Completion Date: 01 Sept 2006
Study Completion Date: 01 Sept 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
N/A
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AC2592 continuous subcutaneous infusion (via pump), dose based on subject body weight |
| Placebo Comparator: 2 | Drug: placebo continuous subcutaneous infusion (via pump), dose based on subject body weight |
Contacts
Investigators
Principal Investigator
Lisa Porter
Amylin Pharmaceuticals
